Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Nkarta, Inc. (NKTX)

Nkarta to host November 9 webcast on initial NKX019 clinical data at ACR 2026

Neutral Impact 2 of 5 product/contract

Nkarta, Inc. announced it will host a webcast on Monday, November 9, 2026, at 8:00 a.m. Eastern Time to review initial clinical data for its NKX019 cell therapy candidate in myositis and systemic sclerosis, presented at the American College of Rheumatology Convergence 2026. The filing contains no financial results, and the company did not disclose the clinical data itself in this document, so shareholders will learn the results at the webcast.

Key points

  • Webcast set for Monday, November 9, 2026, at 8:00 a.m. ET
  • Initial data covers NKX019 in myositis and systemic sclerosis under the Ntrust program
  • Data to be presented at ACR Convergence 2026 in Orlando; replay to be archived on Nkarta's investor website

The filing

CompanyNkarta, Inc. (NKTX)
Form8-K, current report
Filed with the SECNov 6, 2026, 4:04 PM ET
Accession number0001787400-26-000023

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.